Recommendation for post-exposure prophylaxis after potential exposure to herpes b virus in Germany
- PMID: 19941640
- PMCID: PMC2789725
- DOI: 10.1186/1745-6673-4-29
Recommendation for post-exposure prophylaxis after potential exposure to herpes b virus in Germany
Abstract
Although the risk of a herpes B virus (Cercopithecine herpes virus 1) infection is low, the clinical course of the infectious disease is generally unfavourable. A high safety standard can be achieved if people with professional contact to primates apply proper organisational, technical and personal safety precautions. The risk can be considerably reduced if animal keepers, laboratory assistants and scientists receive adequate information about the pathology of herpes B virus and are well trained in the necessary procedures and the precautions. For this reason, comprehensive and regular training, information and instruction must be provided to all primate workers and to laboratory workers who come into contact with potentially infectious material. After potential contamination, the risk for the affected worker must be assessed immediately and post-exposure chemoprophylaxis performed if necessary. This necessitates internal risk assessment. An interdisciplinary group of experts has developed an action plan for Germany.
Similar articles
-
Herpes B virus infection.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Apr;85(4):399-403. doi: 10.1016/s1079-2104(98)90064-6. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998. PMID: 9574948 Review.
-
Marburg and Ebola virus infections in laboratory non-human primates: a literature review.Comp Med. 2000 Apr;50(2):108-23. Comp Med. 2000. PMID: 10857001 Review.
-
[Occupational and non occupational exposure to viral risk].Rev Med Interne. 2019 Apr;40(4):238-245. doi: 10.1016/j.revmed.2018.09.002. Epub 2018 Oct 5. Rev Med Interne. 2019. PMID: 30297152 Review. French.
-
Occupational exposure to HIV infection in health care workers.Med Sci Monit. 2003 May;9(5):CR197-200. Med Sci Monit. 2003. PMID: 12761457
-
Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1).Clin Infect Dis. 2002 Nov 15;35(10):1191-203. doi: 10.1086/344754. Epub 2002 Oct 17. Clin Infect Dis. 2002. PMID: 12410479
Cited by
-
Papiine herpesvirus 2 as a predictive model for drug sensitivity of Macacine herpesvirus 1 (monkey B virus).Comp Med. 2014 Oct;64(5):386-93. Comp Med. 2014. PMID: 25402179 Free PMC article.
-
Effective Prophylactic Therapy for Exposure to Monkey B Virus (Macacine alphaherpesvirus 1).Comp Med. 2020 Feb 1;70(1):56-66. doi: 10.30802/AALAS-CM-18-000134. Epub 2019 Dec 6. Comp Med. 2020. PMID: 31810502 Free PMC article.
-
Chemoprophylaxis of Tropical Infectious Diseases.Pharmaceuticals (Basel). 2010 May 18;3(5):1561-1575. doi: 10.3390/ph3051561. Pharmaceuticals (Basel). 2010. PMID: 27713318 Free PMC article. Review.
-
Understanding Primate Herpesviruses.J Emerg Dis Virol. 2017 Mar;3(1):10.16966/2473-1846.127. doi: 10.16966/2473-1846.127. Epub 2017 Jan 31. J Emerg Dis Virol. 2017. PMID: 29607423 Free PMC article.
References
-
- Holmes GP, Chapman LE, Stewart JA, Straus SE, Hilliard JK, Davenport DS. Guidelines for the prevention and treatment of B-virus infections in exposed persons. The B virus Working Group. Clin Infect Dis. 1995;20(2):421–439. - PubMed
-
- Weigler BJ. Biology of B virus in macaque and human hosts: a review. Clin Infect Dis. 1992;14(2):555–567. - PubMed
Publication types
LinkOut - more resources
Full Text Sources